Antiretroviral resistance in HIV: Difference between revisions
From IDWiki
(→) |
m (Aidan moved page Antiretroviral resistance to Antiretroviral resistance in HIV) |
(No difference)
|
Latest revision as of 12:59, 22 October 2020
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
Common Mutations
- NRTIs
- M184V/I confers resistance to lamivudine, emtricitabine, and abacavir, but increases susceptibility to tenofovir, so combinations that include tenofovir are still safe to use
- K65R confers resistance to lamivudine, emtricitabine, and abacavir
- TAMS (M41L, D76N, K70R, L210W, T215Y, K219Q) confer resistance to basically all NRTIs as they increase in number
- Q151M, 69SSS confers resistance to NRTIs
- NNRTIs
- K103N confers resistance to efavirenz and nevirapine
- Y181C confers resistance to nevirapine and other NNRTIs
- E138K and K101E confer resistance to rilpivirine and other NNRTIs
- I50L confers resistance to atazanavir
- INSTIs
- N155H and Q148H/R?K confer resistance to raltegravir and elvitegravir
- Y143C confers resistance to raltegravir
- R263K confers resistance to dolutegravir
All Mutations
Drug | Mutation | Notes |
---|---|---|
NRTIs | ||
69 insertion complex | M41L | multi-NRTI resistance |
A62V | ||
* 69 insert | ||
K70R | ||
L210W | ||
T215YF | ||
K219QE | ||
151 complex | A62V | multi-NRTI resistance |
V75I | ||
F77L | ||
F116Y | ||
Q151M | ||
Thymidine analogue-associated mutations (TAMs) | M41L | resistance to AZT and d4T; resistance to others is proportional to the number of TAMs, and with 4 or more mutations there is resistance to essentially all NRTIs |
D67N | ||
K70R | ||
L210W | ||
T215Y/F | ||
K219Q/W | ||
Abacavir | K65R/E/N | common |
L74V | ||
Y115F | ||
M184V | common; can still use TDF, AZT | |
Emtricitabine | K65R/E/N | common |
M184V/I | common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF | |
Lamivudine | K65R/E/N | common |
M184V/I | common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF | |
Tenofovir | K65R/E/N | common |
K70E | ||
Zidovudine | M41L | |
D67N | ||
K70R | ||
L210W | ||
T215Y/F | ||
K219Q/E | ||
NNRTIs | ||
Doravirine | V106A/I/M/T | |
Y188C/L/H | ||
G190E | ||
P225H | ||
F227C/L/R | ||
M230L | ||
L234I | ||
Efavirenz | L100I | |
K101P | ||
K103N/S | ||
V106M | ||
V108I | ||
Y181C/I | ||
Y188L | ||
G190S/A | ||
P225H | ||
M230L | ||
Nevirapine | L100I | |
K101P | ||
K103N/S | ||
V106A/M | ||
V108I | ||
Y181C/I | common | |
Y188C/L/H | ||
G190A | ||
M230L | ||
Rilpivirine | L100I | |
K101E/P | common | |
E138A/G/K/Q/R | common | |
V179L | ||
Y181C/I/V | common | |
Y188L | ||
H221Y | ||
F227C | ||
M230I/L | ||
Protease inhibitors | ||
Atazanavir | L10I/F/V/C | |
G16E | ||
K20R/M/I/T/V | ||
L24I | ||
V32I | ||
L33I/F/V | ||
E34Q | ||
M36I/L/V | ||
M46I/L | ||
G48V | ||
I50L | common | |
F53L/Y | ||
I54L/V/M/T/A | ||
D60E | ||
I62V | ||
I64L/M/V | ||
A71V/I/T/L | ||
G73C/S/T/A | ||
V82A/T/F/I | ||
I84V | ||
I85V | ||
N88S | ||
L90M | ||
I93L/M | ||
Darunavir | V11I | |
V32I | ||
L33F | ||
I47V | ||
I50V | ||
I54M/L | ||
T74P | ||
L76V | ||
I84V | ||
L89V | ||
INSTIs | ||
Bictegravir | G118R | |
E138K | ||
G140S | ||
Q148H | ||
R263K | ||
Cabotegravir | T66K | |
G118R | ||
E138A/K/T | ||
G140A/C/R/S | ||
Q148H/K/R | ||
S153F/Y | ||
N155H | ||
R263K | ||
Dolutegravir | G118R | |
F121Y | ||
E138A/K/T | ||
G140A/S | ||
Q148H/K/R | ||
N155H | ||
R263K | common | |
Elvitegravir | T66I/A/K | |
E92Q/G | ||
T97A | ||
F121Y | ||
S147G | ||
Q148H/K/R | common | |
N155H | common | |
R263K | ||
Raltegravir | L74M | |
E92Q | ||
T97A | ||
F121Y | ||
E138A/K | ||
G140A/S | ||
Y143R/H/C | common | |
Q148H/K/R | common | |
N155H | common | |
R263K |